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Abstract
Background: Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic
landscape of a wide range of hematological malignancies. Its prognostic value in acute lymphoblastic leukemia (ALL)
has been established and MRD measured at the end of induction is increasingly used to guide further therapy.
Although MRD detectable immediately before allogeneic hematopoietic cell transplantation (HCT) is known to be
associated with poor outcomes, it is unclear if or to what extent this differs with different types of conditioning.
Methods: In this retrospective registry study, we explored whether measurable residual disease (MRD) before
allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia is associated with different
outcomes in recipients of myeloablative total body irradiation (TBI)-based versus chemotherapy-based conditioning.
We analyzed outcomes of 2780 patients (median age 38 years, range 18–72) who underwent first HCT in complete
remission between 2000 and 2017 using sibling or unrelated donors.
Results: In 1816 of patients, no disease was detectable, and in 964 patients, MRD was positive. Conditioning was TBI-
based in 2122 (76%) transplants. In the whole cohort MRD positivity was a significant independent factor for lower
overall survival (OS) and leukemia-free survival (LFS), and for higher relapse incidence (RI), with respective hazard ratios
(HR, 95% confidence intervals) of 1.19 (1.02–1.39), 1.26 (1.1–1.44), and 1.51 (1.26–1.8). TBI was associated with a higher
OS, LFS, and lower RI with HR of 0.75 (0.62–0.90), 0.70 (0.60–0.82), and 0.60 (0.49–0.74), respectively. No significant
interaction was found between MRD status and conditioning. When investigating the impact of MRD separately in the
TBI and chemotherapy-based conditioning cohorts by multivariate analysis, we found MRD positivity to be associated
with lower OS and LFS and higher RI in the TBI group, and with higher RI in the chemotherapy group. TBI-based
conditioning was associated with improved outcomes in both MRD-negative and MRD-positive patients.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: jiri@pavlu.co.uk
1Centre for Haematology, Imperial College London at Hammersmith
Hospital, Du Cane Road, London W12 0HS, UK
Full list of author information is available at the end of the article
Pavlů et al. Journal of Hematology & Oncology          (2019) 12:108 
https://doi.org/10.1186/s13045-019-0790-x
(Continued from previous page)
Conclusions: In this large study, we confirmed that patients who are MRD-negative prior to HCT achieve superior
outcomes. This is particularly apparent if TBI conditioning is used. All patients with ALL irrespective of MRD status
benefit from TBI-based conditioning in the myeloablative setting.
Keywords: Measurable residual disease, Allogeneic hematopoietic cell transplantation, Acute lymphoblastic leukemia,
Allogeneic, Myeloablative conditioning, Total body irradiation
Background
Assessment of measurable residual disease (MRD) is rapidly
transforming the therapeutic and prognostic landscape of a
wide range of hematological malignancies. Its prognostic
value in acute lymphoblastic leukemia (ALL) has been
established and MRD measured post-induction or consoli-
dation is increasingly used to guide further therapy [1].
The prognostic value of MRD measured prior to allogen-
eic hematopoietic cell transplantation (HCT) on its out-
comes was first observed in small retrospective [2, 3] and
prospective [4] studies of children and adolescents and later
also in adults [5–7], and confirmed in a recent meta-analysis
[8]. However, it remains unclear if or to what extent the
choice of conditioning regimen impacts on this. We have re-
cently studied the interaction of myeloablative versus
reduced-intensity conditioning and MRD in acute myeloid
leukemia [9]. As ALL patients rarely receive reduced-
intensity conditioning, we explored if MRD detectable be-
fore allogeneic HCT for ALL is associated with different
outcomes in recipients of myeloablative total body irradi-
ation (TBI)-based versus chemotherapy-based conditioning.
Methods
Study design and data collection
This was a multicenter, retrospective registry analysis,
approved by the Acute Leukemia Working Party of the
European Society for Blood and Marrow Transplantation
(EBMT). The EBMT is a voluntary group that represents
more than 600 transplant centers, predominantly Euro-
pean. EBMT centers pay annual subscriptions to main-
tain the EBMT Registry.
EBMT Med A/B standardized data collection forms
[10] are submitted to the registry by transplant center
personnel following written informed consent from pa-
tients in accordance with center ethical research guide-
lines. Accuracy of data is assured by the individual
transplant centers and by quality control measures such
as regular internal and external audits. Presence of Phila-
delphia chromosome status was collected. The results of
disease assessments at HCT were also submitted and
form the basis of this report.
Eligibility criteria were age 18 years or older, a diagno-
sis of de novo ALL, disease status at transplant of mor-
phological first complete remission supplemented by a
report of MRD status, recipients of first myeloablative
HCT during the study period 2000 to 2017, a stem cell
source that was either unmanipulated peripheral blood
stem cells or bone marrow and a donor that was a sib-
ling or unrelated 9/10 or 10/10 matched. Table 1 pro-
vides numbers of patients fulfilling the inclusion criteria
and availability of required information in the EBMT
database. MRD methodology and allocation to MRD-
negative or MRD-positive groups were determined by
individual participating centers and utilized molecular
and/or immunophenotyping criteria. An additional audit
of methods used in the EBMT centers contributing to
the study showed that 34 of 56 centers (61%) used both
PCR-based and immunophenotyping-based techniques.
PCR-based techniques only were used in 11 centers and
immunophenotyping only also in 11 centers (19.6%). All
centers but one regarded an MRD level of 10−4 or lower
as negative (for one center this was less than 10−3). In-
tensity of conditioning was allocated in accordance with
published criteria [11].
Statistical methods
Measured outcomes were leukemia-free survival (LFS),
relapse incidence (RI), non-relapse mortality (NRM),
overall survival (OS), acute graft-vs-host disease
(aGVHD), chronic graft-vs-host-disease (cGVHD), and
GVHD-free and relapse-free survival (GRFS). LFS was
defined as survival with no evidence of relapse or pro-
gression. Relapse was defined as a reappearance of blasts
in the blood or bone marrow (> 5%) or in any extrame-
dullary site. NRM was defined as death without evidence
of relapse or progression. OS was defined as the time
from HCT to death, regardless of the cause. GRFS was
defined as survival free of events including grade 3–4
aGVHD, extensive cGVHD, relapse, or death [12].
Probabilities of OS, LFS, and GRFS were calculated
using the Kaplan-Meier method. Cumulative incidence
was used to estimate the endpoints of NRM, RI, aGVHD,
and cGVHD to accommodate competing risks. To study
aGVHD and cGVHD, we considered relapse and death to
be competing risks. Univariate analyses were done using
Gray’s test for cumulative incidence functions and the log-
rank test for OS, GRFS, and LFS. A Cox proportional
hazards model was used for multivariate regression. All
variables differing significantly between the two groups or
factors known to influence outcomes were included in the
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Cox model. In order to test for a center effect, we intro-
duced a random effect or frailty for each center into the
model [13, 14]. Results were expressed as the hazard ratio
(HR) with the 95% confidence interval (95% CI). The type
I error rate was fixed at 0.05 for the determination of
factors associated with time-to-event outcomes.
After analysis of the whole group, two separate planned
sub-analyses of TBI-based conditioning and chemother-
apy only conditioning were made. Statistical analyses were
performed with SPSS 24.0 (SPSS Inc., Chicago, IL) and R
3.4.1 (R Core Team 2017) [15].
Results
Demographics and transplant details
A total of 2780 patients from 301 transplant centers
were eligible. Median age at transplantation was 38 years
(range 18–72). In 1816 (65%) of patients, no disease was
detectable, and in 964 (35%) patients, MRD was positive.
Conditioning was TBI-based in 2122 (76%) transplants
and chemotherapy-based in 658 (24%) transplants. De-
tails of patient and transplant characteristics by MRD
status are summarized in Table 2. More patients with
Philadelphia chromosome-positive B-ALL were MRD-
positive at transplantation (66 versus 49%, P < .001).
Patients who were MRD-negative at the time of trans-
plantation were less likely to receive donor lymphocytes
after the procedure (7% versus 12%, P < .001). With a
medium follow-up of 42 months the probability of OS,
LFS, GRSF, and RI at 2 years for the whole cohort was
65% (95% CI 63–70), 55% (95% CI 53–57), 42% (95% CI
39–44), and 27% (95% CI 25–29), respectively.
Univariate analysis
Compared to MDR-negative status MRD-positive status at
the time of transplantation was associated with significantly
worse probability of OS (61% versus 67%), LFS (50% versus
58%), GRFS (35% versus 45%), and with higher RI (32% ver-
sus 24%) at 2 years post-transplantation. The full results of
univariate analysis are summarized in Additional file 2.
Multivariate analysis
The results of multivariate analysis by Cox regression
showed MRD positivity was a significant independent
factor for lower survival and LFS, and for higher RI, with
respective HR of 1.19 (95% CI 1.02–1.39), 1.26 (95% CI
1.1–1.44), and 1.51 (95% CI 1.26–1.8). Of the potentially
modifiable factors, use of TBI-based conditioning was
associated with a higher OS, LFS, and lower RI with HR
of 0.75 (95% CI 0.62–0.90), 0.70 (95% CI 0.60–0.82), and
0.60 (95% CI 0.49–0.74), respectively. Use of in vivo T
cell depletion was associated with decreased NRM, im-
proved GRFS, lower incidence acute grade II–IV, grade
III–IV, chronic, and extensive chronic GVHD, with HR
of 0.68 (95% CI 0.52–0.88), 0.75 (95% CI 0.64–0.88),
0.72 (95% CI 0.59–0.89), 0.51 (95% CI 0.35–0.75), 0.58
(95% CI 0.47–0.71), and 0.48 (95% CI 0.36–0.64), re-
spectively. The prognostic impact of MRD status did not
differ significantly according to the conditioning. Results
of multivariate analysis of the whole cohort are summa-
rized in Table 3.
When investigating the impact of MRD separately in the
TBI and chemotherapy-based conditioning cohorts by
multivariate analysis, we found MRD positivity to be asso-
ciated with lower OS and LFS and higher RI in the TBI
group, and with higher RI in the chemotherapy group (re-
sults are summarized in Additional file 3). TBI-based con-
ditioning was associated with improved outcomes in both
MRD-negative and MRD-positive patients (Fig. 1).
Discussion
In this large study, we confirmed that adult patients with
ALL who are MRD-negative prior to allogeneic HCT
achieve superior outcomes, namely, lower RI, higher LFS,
and OS. We were interested in exploring potential differ-
ing outcomes between recipients of TBI-based condition-
ing and conditioning based on chemotherapy only. While
TBI-based conditioning is associated with significant short
as well as long-term toxicity [16], it remains part of most
conditioning protocols for ALL because it is believed to
have a better anti-leukemic potential in lymphoid malig-
nancies. In animal experiments, administration of high
doses of busulfan had little impact on lymphoid organs
[17] or on antibody responses [18]. In children, a small
randomized trial [19] showed better event-free survival
with TBI-based regiments, and a recent large international
randomized trial closed, after an interim analysis showed a
survival benefit in patients who received TBI-based condi-
tioning over chemotherapy-based conditioning [20]. There
are no such randomized prospective trials in adults, but
data in many retrospective studies, including recently
Table 1 Numbers of patients fulfilling the inclusion criteria with required information
Inclusion criteria N
Adults with ALL in CR1 or CR2 allografted from MSD or UD 10/10 or UD 9/10 from January 2000 to December 2017 10,418
Myeloablative conditioning 8400
Available information
Immunophenotype B or T and Philadelphia status 5540
MRD status before transplantation reported 2780
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Table 2 Demographics and transplant details
Characteristic MRD negative MRD positive P
N 1816 964
Median follow-up, (months, IQR) 39.70 (12.89–84.20) 44.56 (16.07–82.07) 0.410
Median age (years, range, IQR) 36 (18–70, 26–46) 38 (18–72, 28–48) < 0.001
Median time dg to HCT (months, range, IQR) 5.7 (1.9–130, 4.6–8) 5.6 (2.3–123, 4.5–7.7) 0.182
Median year of HCT (range) 2012 (2000–2017) 2012 (2000–2017) 0.687
Median donor age (years, range, IQR, missing) 34 (4–73, 26–44, 643) 35 (10–72, 27–44, 293) 0.080
In vivo TCD 0.221
No in vivo TCD 1099 (62%) 565 (60%)
In vivo TCD 670 (38%) 381 (40%)
Data missing 47 18
Remission status at HCT 0.518
CR1 1580 (87%) 847 (88%)
CR2 236 (13%) 117 (12%)
ALL subtype < 0.001
B-ALL Ph-negative 479 (26%) 181 (19%)
B-ALL Ph-positive 882 (49%) 639 (66%)
T-ALL 455 (25%) 144 (15%)
Karnofsky score at HCT 0.203
< 80% 60 (4%) 41 (5%)
> =80% 1639 (96%) 861 (95%)
Data missing 117 62
Engraftment 0.459
Engrafted 1732 (98%) 925 (99%)
Graft failure 29 (1.7%) 12 (1.3%)
Data missing 55 27
Source of stem cells 0.008
Bone marrow 409 (23%) 261 (27%)
Blood 1407 (78%) 703 (73%)
Donor type 0.268
Matched sibling 1041 (57%) 531 (55%)
Unrelated 10/10 match 575 (32%) 308 (32%)
Unrelated 9/10 match 200 (11%) 125 (13%)
Conditioning 0.628
Chemotherapy-based 435 (24%) 223 (23%)
TBI containing 1381 (76%) 741 (77%)
Patient sex 0.285
Male 1097 (60%) 603 (63%)
Female 717 (40%) 361 (37%)
Data missing 2 0
Donor sex 0.267
Male 1107 (62%) 606 (64%)
Female 693 (39%) 346 (36%)
Data missing 16 12
Donor–recipient sex mismatch 0.411
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published large analysis by the EBMT suggested advan-
tages of TBI-based over chemotherapy-based regimens,
particularly in terms of reduced risk of relapse and im-
proved LFS [21]. This effect was also seen in adults trans-
planted for primary refractory ALL [22] with a large
tumor bulk as well as in patients with T-ALL, regardless
of their remission status [23]. So far, however, the impact
of conditioning has not been studied in the context of
MRD. It has been unclear if TBI is necessary for patients
who achieved MRD negativity as a graft-versus-leukemia
Table 2 Demographics and transplant details (Continued)
Characteristic MRD negative MRD positive P
Female to male 391 (22%) 195 (20%)
Other 1409 (78%) 762 (80%)
Data missing 16 7
Patient CMV serology 0.950
Negative 637 (37%) 342 (37%)
Positive 1090 (63%) 582 (63%)
Data missing 89 40
Donor CMV serology 0.690
Negative 790 (46%) 414 (45%)
Positive 927 (54%) 502 (55%)
Data missing 99 48
CMV donor/recipient 0.975
Negative to negative 450 (27%) 239 (27%)
Positive to negative 176 (10%) 99 (11%)
Negative to positive 317 (19%) 166 (18%)
Positive to positive 743 (44%) 398 (44%)
Data missing 130 62
HCT-comorbidity index 0.128
1 or 2 529 (85%) 271 (81%)
> =3 92 (15%) 62 (19%)
Data missing 1195 631
GVHD prevention 0.054
Cyclosporin 124 (7%) 60 (6%)
Cyclosporin and MTX 1247 (70%) 702 (74%)
Cyclosporin and MMF ±MTX 181 (10%) 101 (11%)
Tacrolimus ± other 115 (7%) 41 (4%)
Other 103 (6%) 41 (4%)
Data missing 46 19
Acute GVHD 0.139
Grade 0–I 1156 (67%) 594 (64%)
Grade II–IV 564 (33%) 329 (36%)
Data missing 96 41
Donor lymphocyte infusion < 0.001
None received 1681 (93%) 846 (88%)
Pre-emptive 36 (2%) 48 (5%)
After relapse 97 (5%) 67 (7%)
Data missing 2 3
Abbreviations: CR complete remission, CMV cytomegalovirus, GVHD graft-versus-host disease, HCT hematopoietic cell transplantation, IQR interquartile range, dg
diagnosis, MMF mycophenolate mofetil, MTX methotrexate; MRD measurable residual disease, Ph Philadelphia chromosome/BCR-ABL gene rearrangement, TCD T
cell depletion
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effect may be sufficient to eliminate very low level of re-
sidual disease.
This study showed significantly superior outcomes
with the use of TBI-based conditioning in both MRD-
positive and MDR-negative patients, but the impact of
MRD did not differ significantly between the TBI-based
or chemotherapy-based conditioning. MRD positivity
was associated with lower OS and LFS and higher RI in
the larger (n = 1943) TBI subgroup, and with higher RI
in the smaller (n = 571) chemotherapy subgroup. The
reasons for this cannot be concluded from this study,
but it is possible that ALL cells are able to escape the ef-
fect of chemotherapy in sanctuary sites such as CNS,
and/or that the ALL is simply more susceptible to effects
of radiotherapy. No patients received radiotherapy be-
fore starting transplantation conditioning, so irradiation
represents a different anti-leukemic treatment modality
to chemotherapy in patients transplanted after TBI-
based conditioning. Also, patients in this cohort did not
receive modern immunotherapy such as inotuzumab,
ozogamicin, or blinatumomab that are able to induce
MRD negativity on their own [24, 25] or in addition to
chemotherapy [26, 27]. It is likely that with the use of
these agents, more patients may become MRD-negative.
Whether they will or will not benefit from TBI-based
conditioning as the MRD-negative patients in this cohort
remains unclear, but clinicians should not rush into
rejecting TBI-based conditioning in patients with ALL.
Compared to related donors, unrelated donors both
10/10 and 9/10 had a lower incidence of relapse. This
suggests better anti-leukemic activity and increased
GVHD with lower degree of histocompatibility. Unlike
in recent studies of T cell-replete haploidentical trans-
plantation with post-transplantation cyclophosphamide
[28, 29], this increase in anti-leukemic activity did not
improve OS due to higher incidence of aGVHD,
cGVHD, and NRM.
Interestingly, in vivo T cell depletion was associated
with higher RI, lower NRM, and lower incidence of
aGVHD and cGVHD only in patients who received TBI-
based, but not chemotherapy-based conditioning. This
phenomenon may suggest more profound immune allo-
geneic effect in conjunction with the use of TBI-based
conditioning, perhaps due to more significant lymphode-
pletion seen in animal experiments after TBI but not after
chemotherapy [17, 18]. Some previous publications sug-
gested an increased incidence of GVHD after TBI-based
conditioning [30, 31], but there is also data in contrary to
this [32]. Surprisingly, in the chemotherapy-based, but not
TBI-based conditioning subgroup, MRD-positive patients
experienced higher RI, but comparable LFS and OS.
Although it is possible to speculate that patients who
relapsed after chemotherapy-based conditioning benefited
more from salvage treatments with donor lymphocytes,
the difference may be also due to the size of the groups
and resulting statistical power.
Although the majority of EBMT centers use highly
sensitive methods of MDR detection [33], and our an
additional audit showed that all 56 centers but 1
regarded an MRD level of 10−4 or lower as negative (for
one center this was less than 10−3), an obvious limitation
of this registry study is the lack of access to details of
MRD methodologies and targets used in individual
patients. However, the proportion of reported MRD-
positive cases seen was 35% of the total eligible for the
study and this is similar to the 21 to 38% reported in
studies where detailed review of MRD methodology and
targets were feasible [34, 35]. Centers were required to
declare the MRD status of patients prior to HCT, but we
did not have access to the precise timing of the relevant
Fig. 1 Survival of 2780 adults transplanted for ALL after myeloablative conditioning. Kaplan-Meier curves show estimates of leukemia-free survival
(LFS, left) and overall survival (OS, right). Curves for patients with undetectable MRD (MRD neg) at transplantation are shown in full lines, and for
MRD-positive (MRD pos) patients in broken lines. Curves related to TBI-based conditioning are shown black and to chemotherapy-based
conditioning in gray lines
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MRD assay. Another important issue is potential hetero-
geneity of conditioning regimens within the TBI and
chemotherapy groups [36].
The challenge of how best to manage MRD positivity
pre-HCT in the clinic is a familiar dilemma since further
therapy may incur toxicity that renders subsequent HCT
undeliverable or may result in frank relapse should the
leukemia show resistance to the new treatment modality.
In the post-HCT setting, management of MRD-positive
patients has involved strategies such as rapid withdrawal
of immunosuppressive medication, pre-emptive use of
donor lymphocyte infusions, and maintenance therapy
with tyrosine kinase inhibitors in Philadelphia-positive
patients. In the future, immunotherapy such as blinatumo-
mab [37], chimeric antigen receptor T cells, natural killer
cells, or check-point inhibitors may be useful mostly in
patients with B cell ALL.
Conclusions
In this large study, we confirmed that adult patients with
acute lymphoblastic leukemia who are MRD-negative
prior to HCT achieve superior outcomes. This was par-
ticularly apparent with the use of TBI-based conditioning.
With increasing availability of new therapies MRD nega-
tivity is likely to become achievable for more patients,
hopefully leading to improved treatment outcomes. As all
patients with ALL irrespective of MRD status benefit from
TBI-based conditioning, avoidance of it on the basis of
achievement of MRD negativity is not justified.
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